Molecular Pathology Laboratory Network

HPV G

HPV Type 16/18, cervical cancer

INVADER® genotyping system

83891 - Molecular isolation
83892 x4 - Enzymatic digestion
83896 x6 - Each nulcleic acid probe
83903 x2 - Mutation scanning each
88908 x2 - Amplfication each sequence
83912 - Interpretation and report

7-10 days

2.0 mL liquid cytology media (ThinPrep® PAP solution or SurePath™ Test Pack solution)

Stable at 18-25°C for 21 days

Ship at ambient

Insufficient specimen; Low sample cellularity

HPV HR type 16, 18 or 16/18 Detected/Not Detected

HPV High risk detection

To be used adjunctively, with an FDA approved HPV high risk test, in patients with either a HPV HR+ ASC-US result or, in women 30 years of age and older, with a HPV HR+ primary screening result.

1. American Society for Colposcopy and Cervical Pathology
2. Meijer CJ et al. (2006). Clinical utility of HPV genotyping. Gynecol Oncol. 103:12-17.
3. Khan MJ et al. (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. JNCI. 97:1072-1079.
4. Munoz N et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEJM. 348:518-527.

Invader is a registered trademark of Third Wave Technologies, Inc., a wholly-owned subsidiary of Hologic, Inc.
ThinPrep is a registered trademark of Cytyc Corportation.
SurePath is a trademark of Becton, Dickinson and Company.